OncoQuest Pharmaceuticals Inc (078590) - Net Assets
Based on the latest financial reports, OncoQuest Pharmaceuticals Inc (078590) has net assets worth ₩74.92 Billion KRW (≈ $50.77 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩94.30 Billion ≈ $63.91 Million USD) and total liabilities (₩19.38 Billion ≈ $13.13 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore total assets of OncoQuest Pharmaceuticals Inc for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩74.92 Billion |
| % of Total Assets | 79.45% |
| Annual Growth Rate | 19.18% |
| 5-Year Change | 98.09% |
| 10-Year Change | N/A |
| Growth Volatility | 22.44 |
OncoQuest Pharmaceuticals Inc - Net Assets Trend (2014–2025)
This chart illustrates how OncoQuest Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Check OncoQuest Pharmaceuticals Inc (078590) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for OncoQuest Pharmaceuticals Inc (2014–2025)
The table below shows the annual net assets of OncoQuest Pharmaceuticals Inc from 2014 to 2025. For live valuation and market cap data, see 078590 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩48.94 Billion ≈ $33.17 Million |
+2.14% |
| 2024-12-31 | ₩47.92 Billion ≈ $32.47 Million |
+10.35% |
| 2023-12-31 | ₩43.42 Billion ≈ $29.43 Million |
+25.14% |
| 2022-12-31 | ₩34.70 Billion ≈ $23.51 Million |
+40.43% |
| 2019-12-31 | ₩24.71 Billion ≈ $16.74 Million |
-5.48% |
| 2018-12-31 | ₩26.14 Billion ≈ $17.71 Million |
+50.96% |
| 2017-12-31 | ₩17.32 Billion ≈ $11.73 Million |
+21.12% |
| 2016-12-31 | ₩14.30 Billion ≈ $9.69 Million |
+19.32% |
| 2015-12-31 | ₩11.98 Billion ≈ $8.12 Million |
+68.72% |
| 2014-12-31 | ₩7.10 Billion ≈ $4.81 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to OncoQuest Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 25341843260000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩316.95 Billion | 647.59% |
| Total Equity | ₩48.94 Billion | 100.00% |
OncoQuest Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of OncoQuest Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Emporiki Eisagogiki Aftokiniton Ditrohon kai Mihanon Thalassis Societe Anonyme
AT:MOTO
|
$69.95 Million |
|
TPL Plastech Limited
NSE:TPLPLASTEH
|
$69.96 Million |
|
Marchex Inc
NASDAQ:MCHX
|
$69.99 Million |
|
DocCheck AG
XETRA:AJ91
|
$70.00 Million |
|
Johnson Chemical Pharmaceutical Works Co Ltd
TWO:4747
|
$69.93 Million |
|
Next Technology Holding Inc
NASDAQ:NXTT
|
$69.92 Million |
|
Hwa Sung Ind
KO:002460
|
$69.91 Million |
|
Vitura S.A.
PA:VTR
|
$69.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in OncoQuest Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 47,915,397,140 to 48,942,253,810, a change of 1,026,856,670 (2.1%).
- Net loss of 11,121,566,330 reduced equity.
- Share repurchases of 2,284,200 reduced equity.
- New share issuances of 5,934,053,520 increased equity.
- Other factors increased equity by 6,216,653,680.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-11.12 Billion | -22.72% |
| Share Repurchases | ₩2.28 Million | -0.0% |
| Share Issuances | ₩5.93 Billion | +12.12% |
| Other Changes | ₩6.22 Billion | +12.7% |
| Total Change | ₩- | 2.14% |
Book Value vs Market Value Analysis
This analysis compares OncoQuest Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.37x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | ₩5901.18 | ₩1955.00 | x |
| 2023-12-31 | ₩7311.44 | ₩1955.00 | x |
| 2024-12-31 | ₩8068.91 | ₩1955.00 | x |
| 2025-12-31 | ₩5242.23 | ₩1955.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently OncoQuest Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -22.72%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -17.28%
- • Asset Turnover: 0.79x
- • Equity Multiplier: 1.67x
- Recent ROE (-22.72%) is below the historical average (3.70%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 9.51% | 1.84% | 2.20x | 2.35x | ₩-34.52 Million |
| 2015 | 11.02% | 3.33% | 2.10x | 1.58x | ₩121.69 Million |
| 2016 | 17.44% | 6.38% | 1.81x | 1.51x | ₩1.06 Billion |
| 2017 | 15.00% | 6.49% | 1.45x | 1.59x | ₩866.33 Million |
| 2018 | -25.35% | -15.27% | 0.62x | 2.68x | ₩-9.24 Billion |
| 2019 | -24.48% | -9.36% | 0.90x | 2.91x | ₩-8.52 Billion |
| 2022 | 28.05% | 22.36% | 0.99x | 1.27x | ₩6.26 Billion |
| 2023 | 18.89% | 12.88% | 1.17x | 1.25x | ₩3.86 Billion |
| 2024 | 9.60% | 6.54% | 0.93x | 1.57x | ₩-193.92 Million |
| 2025 | -22.72% | -17.28% | 0.79x | 1.67x | ₩-16.02 Billion |
Industry Comparison
This section compares OncoQuest Pharmaceuticals Inc's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| OncoQuest Pharmaceuticals Inc (078590) | ₩74.92 Billion | 9.51% | 0.26x | $69.94 Million |
| Samyang Holdings Corp (000075) | $2.43 Trillion | 9.80% | 0.84x | $17.20 Million |
| POBIS TNC CO. Ltd (016670) | $50.02 Billion | -5.00% | 0.62x | $57.81 Million |
| Posco ICT Company Ltd (022100) | $259.57 Billion | 6.74% | 1.46x | $2.80 Billion |
| Osung Advanced Materials Co. Ltd (052420) | $200.34 Billion | -5.65% | 0.52x | $335.47 Million |
| Kyung Nam Pharm Co Ltd (053950) | $16.82 Billion | 0.77% | 1.69x | $10.25K |
| ilShinbiobase Co. Ltd (068330) | $57.06 Billion | 10.92% | 0.06x | $26.14 Million |
| Kuk-Il Paper Mfg Co.Ltd (078130) | $67.72 Billion | -12.16% | 1.08x | $337.93 Million |
| MCNEX Co. Ltd (097520) | $54.87 Billion | 4.32% | 1.72x | $328.51 Million |
| Smac Co. Ltd (097780) | $234.40 Billion | -26.91% | 0.29x | $203.48 Million |
About OncoQuest Pharmaceuticals Inc
DIAC Co., Ltd. engages in the car interior and exterior materials business in South Korea and internationally. DIAC Co., Ltd. was founded in 1993 and is headquartered in Miryang-si, South Korea.